Publications by authors named "D Labeit"

Article Synopsis
  • Chronic heart failure (CHF) leads to diaphragm muscle dysfunction, impacting the patient's quality of life and prognosis, prompting research into potential treatments.
  • In a study involving mice with CHF, a small-molecule inhibitor (ID#704946) targeting MuRF1 was tested against a control diet to see its effects on diaphragm health and function.
  • Results showed that while CHF caused diaphragm muscle atrophy and reduced function, the treatment with ID#704946 helped preserve muscle contractility and improve mitochondrial enzyme activity, although the exact mechanisms are still unclear.
View Article and Find Full Text PDF

Background: Muscle ring finger 1 (MuRF1) is a muscle-specific ubiquitin E3 ligase activated during clinical conditions associated with skeletal muscle wasting. Yet, there remains a paucity of therapeutic interventions that directly inhibit MuRF1 function, particularly in vivo. The current study, therefore, developed a novel compound targeting the central coiled coil domain of MuRF1 to inhibit muscle wasting in cardiac cachexia.

View Article and Find Full Text PDF

. Parvovirus B19 (B19V) is a common finding in endomyocardial biopsy specimens from myocarditis and dilated cardiomyopathy patients. However, current understanding of how B19V is contributing to cardiac damage is rather limited due to the lack of appropriate mice models.

View Article and Find Full Text PDF

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies targeting the neuromuscular junction of skeletal muscles. Triple-seronegative MG (tSN-MG, without detectable AChR, MuSK and LRP4 antibodies), which accounts for ~10% of MG patients, presents a serious gap in MG diagnosis and complicates differential diagnosis of similar disorders. Several AChR antibody positive patients (AChR-MG) also have antibodies against titin, usually detected by ELISA.

View Article and Find Full Text PDF